Imperva (NASDAQ:IMPV) had its price objective raised by research analysts at Morgan Stanley from $37.00 to $39.00 in a research note issued to investors on Friday. The firm presently has an “underweight” rating on the software maker’s stock. Morgan Stanley’s price target would suggest a potential downside of 16.22% from the company’s current price.
IMPV has been the topic of a number of other research reports. Piper Jaffray Companies restated a “neutral” rating and set a $58.00 target price on shares of Imperva in a research note on Friday, October 13th. JPMorgan Chase & Co. cut shares of Imperva from a “neutral” rating to an “underweight” rating and set a $45.00 target price on the stock. in a research note on Tuesday, December 12th. Zacks Investment Research cut shares of Imperva from a “buy” rating to a “hold” rating in a research note on Wednesday, January 10th. KeyCorp restated a “hold” rating on shares of Imperva in a research note on Tuesday, October 24th. Finally, Evercore ISI restated a “buy” rating and set a $56.00 target price on shares of Imperva in a research note on Wednesday, November 8th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and eleven have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $52.57.
Shares of Imperva (IMPV) traded up $4.50 during trading hours on Friday, hitting $46.55. 2,138,319 shares of the stock traded hands, compared to its average volume of 355,933. Imperva has a 52-week low of $37.17 and a 52-week high of $52.40. The company has a market cap of $1,471.10, a PE ratio of 172.41 and a beta of 1.79.
Institutional investors have recently added to or reduced their stakes in the company. New York State Common Retirement Fund raised its position in shares of Imperva by 5.3% during the second quarter. New York State Common Retirement Fund now owns 35,800 shares of the software maker’s stock valued at $1,713,000 after buying an additional 1,793 shares during the last quarter. Prudential Financial Inc. raised its position in shares of Imperva by 80.7% during the third quarter. Prudential Financial Inc. now owns 54,174 shares of the software maker’s stock valued at $2,351,000 after buying an additional 24,190 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Imperva by 11.9% during the third quarter. Wells Fargo & Company MN now owns 213,953 shares of the software maker’s stock valued at $9,285,000 after buying an additional 22,741 shares during the last quarter. American Century Companies Inc. bought a new stake in shares of Imperva during the third quarter valued at approximately $6,832,000. Finally, Allianz Asset Management GmbH raised its position in shares of Imperva by 58.1% during the third quarter. Allianz Asset Management GmbH now owns 59,149 shares of the software maker’s stock valued at $2,567,000 after buying an additional 21,732 shares during the last quarter. Hedge funds and other institutional investors own 96.61% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/09/imperva-impv-given-new-39-00-price-target-at-morgan-stanley.html.
Imperva Company Profile
Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.
Receive News & Ratings for Imperva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva and related companies with MarketBeat.com's FREE daily email newsletter.